[2 March 2009 – Hong Kong] Lee's Pharmaceutical Holdings Limited (“Lee's Pharmaceutical” or the “Group”, Stock Code: 8221), an integrated research-driven and market-oriented pharmaceutical group in China, announced today a signing of a license agreement with Nippon Shinyaku Co., Ltd. (“Nippon Shinyaku”), a listed pharmaceutical company in Japan, for the pharmaceutical product containing Nippon Shinyaku’s antibacterial agent “Prulifloxacin”.